MX2020008062A - Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio. - Google Patents

Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio.

Info

Publication number
MX2020008062A
MX2020008062A MX2020008062A MX2020008062A MX2020008062A MX 2020008062 A MX2020008062 A MX 2020008062A MX 2020008062 A MX2020008062 A MX 2020008062A MX 2020008062 A MX2020008062 A MX 2020008062A MX 2020008062 A MX2020008062 A MX 2020008062A
Authority
MX
Mexico
Prior art keywords
nucleic acid
antibodies
acid constructs
use against
against respiratory
Prior art date
Application number
MX2020008062A
Other languages
English (en)
Inventor
David Weiner
Trevor Smith
Katherine Schultheis
Jing Chen
Kar Muthumani
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Publication of MX2020008062A publication Critical patent/MX2020008062A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente descripción se describe una composición que incluye una secuencia de ácido nucleico recombinante que codifica un anticuerpo para un antígeno del Virus Sincicial Respiratorio; también se describe en la presente descripción un método para generar un anticuerpo sintético en un sujeto mediante la administración de la composición al sujeto; la descripción también proporciona un método para prevenir y/o tratar una infección por el virus Sincicial Respiratorio en un sujeto mediante el uso de dicha composición y método de generación.
MX2020008062A 2018-01-31 2019-01-31 Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio. MX2020008062A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624320P 2018-01-31 2018-01-31
US201862749580P 2018-10-23 2018-10-23
PCT/US2019/015975 WO2019152600A1 (en) 2018-01-31 2019-01-31 Nucleic acid antibody constructs for use against respiratory syncytial virus

Publications (1)

Publication Number Publication Date
MX2020008062A true MX2020008062A (es) 2020-12-03

Family

ID=67478343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008062A MX2020008062A (es) 2018-01-31 2019-01-31 Constructos de ácido nucleico de anticuerpos para usar contra el virus sincicial respiratorio.

Country Status (11)

Country Link
US (1) US20210047390A1 (es)
EP (1) EP3746474A4 (es)
JP (1) JP2021512600A (es)
KR (1) KR20200140799A (es)
CN (1) CN111936513A (es)
AU (1) AU2019215006A1 (es)
BR (1) BR112020015588A2 (es)
CA (1) CA3089717A1 (es)
MX (1) MX2020008062A (es)
SG (1) SG11202007241WA (es)
WO (1) WO2019152600A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69609188T2 (de) * 1995-09-18 2000-12-21 Intracel Corp., Issaquah Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
EP1467768A1 (en) * 2001-11-26 2004-10-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Increasing electro-gene transfer of nucleic acid molecules into host tissue
GB0306618D0 (en) * 2003-03-22 2003-04-30 Univ Newcastle Antibody
MX2012003282A (es) * 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
US8568726B2 (en) * 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
PH12012502244A1 (en) * 2010-07-09 2016-09-30 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
TWI659968B (zh) * 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
SG11201604719WA (en) * 2013-12-13 2016-07-28 Univ Pennsylvania Dna antibody constructs and method of using same
EP4353316A3 (en) * 2014-01-15 2024-08-21 Medimmune Limited Rsv-specific antibodies and functional parts thereof
US10202455B2 (en) * 2015-05-20 2019-02-12 Immunwork Inc. Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod
JO3555B1 (ar) * 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EA201892525A1 (ru) * 2016-05-05 2019-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Конструкции днк-антител для применения против pseudomonas aeruginosa

Also Published As

Publication number Publication date
EP3746474A1 (en) 2020-12-09
KR20200140799A (ko) 2020-12-16
EP3746474A4 (en) 2021-12-15
JP2021512600A (ja) 2021-05-20
BR112020015588A2 (pt) 2021-01-05
CN111936513A (zh) 2020-11-13
CA3089717A1 (en) 2019-08-08
SG11202007241WA (en) 2020-08-28
WO2019152600A1 (en) 2019-08-08
AU2019215006A1 (en) 2020-09-17
US20210047390A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
MX2015013065A (es) Proteinas f de rsv de prefusion y su uso.
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
MX2016016533A (es) Combinaciones inmunogenas.
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
MX2018014573A (es) Vacuna contra el virus del zika.
MX2018013525A (es) Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa.
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
AR082149A1 (es) Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
PE20231376A1 (es) Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos
MX2024000118A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
MX2022002963A (es) Composiciones y metodos para tratar nefritis lupica.
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
CL2019003393A1 (es) Virus oncolíticos y método.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
PE20211295A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
MX2018013172A (es) Metodos para el tratamiento de las enfermedades en las que es perjudicial la actividad de la il-13, a traves del uso de los anticuerpos anti-il-13.
AR116878A1 (es) Vacuna de ibv h52 con proteína espicular heteróloga
CO2020009043A2 (es) Anticuerpos humanos contra hemaglutinina de influenza
MX2014006248A (es) Anticuerpos nonoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs).
AR112405A1 (es) Tratamiento de cáncer de mama triple negativo o cáncer colorrectal con metástasis hepáticas